GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA

Antiplatelet therapy is one of the most importance in therapy of patients with injured coronary, cerebral and peripheral arteries. The standard of acute coronary syndrome patients treatment is double antiplatelet therapy: acetylsalicylic acid with P2Y12receptor blocker. Some distinguished genetic sp...

Full description

Bibliographic Details
Main Authors: K. B. Mirzaev, D. A. Sychev, D. A. Andreev
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2015-10-01
Series:Российский кардиологический журнал
Subjects:
clopidogrel
resistance
pharmacogenomics
acute coronary syndrome
cyp2c19
pon-1
ces1
cyp4f2
5-httlpr
Online Access:https://russjcardiol.elpub.ru/jour/article/view/323
Description
Summary:Antiplatelet therapy is one of the most importance in therapy of patients with injured coronary, cerebral and peripheral arteries. The standard of acute coronary syndrome patients treatment is double antiplatelet therapy: acetylsalicylic acid with P2Y12receptor blocker. Some distinguished genetic specifics might lead to the development of resistance to antiplatelet therapy with further thrombotic complications. Current review focuses on the pharmacogenetic specifics of patients than lead clopidogrel resistance.
ISSN:1560-4071
2618-7620

Similar Items